Androgen Receptor Is a Non-canonical Inhibitor of Wild-Type and Mutant Estrogen Receptors in Hormone Receptor-Positive Breast Cancers

Androgen Receptor Is a Non-canonical Inhibitor of Wild-Type and Mutant Estrogen Receptors in Hormone Receptor-Positive Breast Cancers

Summary: Sustained treatment of estrogen receptor (ER)-positive breast cancer with ER-targeting drugs results in ER mutations and refractory unresponsive cancers. Androgen receptor (AR), which is expressed in 80%–95% of ER-positive breast cancers, could serve as an alternate therapeutic target. Alth...

Full description

Bibliographic Details
Main Authors: Suriyan Ponnusamy, Sarah Asemota, Lee S. Schwartzberg, Fouzia Guestini, Keely M. McNamara, Mariaelena Pierobon, Alba Font-Tello, Xintao Qiu, Yingtian Xie, Prakash K. Rao, Thirumagal Thiyagarajan, Brandy Grimes, Daniel L. Johnson, Martin D. Fleming, Frances E. Pritchard, Michael P. Berry, Roy Oswaks, Richard E. Fine, Myles Brown, Hironobu Sasano, Emanuel F. Petricoin, Henry W. Long, Ramesh Narayanan
Format: Article
Language:English
Published: Elsevier 2019-11-01
Series:iScience
Online Access:http://www.sciencedirect.com/science/article/pii/S2589004219304183

Internet

http://www.sciencedirect.com/science/article/pii/S2589004219304183

Similar Items